Search

Displaying results 2771 - 2780 of 10000 in total
  1. Drug

    Iodamide

    go.drugbank.com/drugs/DB08948
    ApprovedWithdrawn

    Iodamide is a contrast medium molecule that is no longer marketed in the United States.

    Categories: Compounds used in a research, industrial, or household setting
  2. Drug

    Streptococcus pneumoniae type 7F capsular polysaccharide diphtheria CRM197 protein conjugate antigen

    go.drugbank.com/drugs/DB10297
    ApprovedInvestigational

    The saccharides in the vaccine are prepared from purified polysaccharides that are chemically activated then conjugated to the protein carrier CRM197 to form the glycoconjugate. … Streptococcus pneumoniae type 7F capsular polysaccharide diphtheria CRM197 protein conjugate antigen is a sterile vaccine that contains saccharides of the capsular antigens of *Streptococcus pneumoniae

    Mixtures: PREVENAR 13/0,5 ML IM ENJEKSIYON ICIN SUS. ICEREN KUL.HAZIR ENJEKTOR, PREVENAR 13/0,5 ML IM ENJEKSIYON ICIN SUS. ICEREN KUL.HAZIR ENJEKTOR, 10 ADET
  3. Drug

    Streptococcus pneumoniae type 19A capsular polysaccharide diphtheria CRM197 protein conjugate antigen

    go.drugbank.com/drugs/DB10298
    ApprovedInvestigational

    The saccharides in the vaccine are prepared from purified polysaccharides that are chemically activated then conjugated to the protein carrier CRM197 to form the glycoconjugate. … Streptococcus pneumoniae type 19a capsular polysaccharide diphtheria CRM197 protein conjugate antigen is a sterile vaccine that contains saccharides of the capsular antigens of *Streptococcus pneumoniae

    Mixtures: PREVENAR 13/0,5 ML IM ENJEKSIYON ICIN SUS. ICEREN KUL.HAZIR ENJEKTOR, PREVENAR 13/0,5 ML IM ENJEKSIYON ICIN SUS. ICEREN KUL.HAZIR ENJEKTOR, 10 ADET
  4. Drug

    Clenbuterol

    go.drugbank.com/drugs/DB01407
    ApprovedInvestigationalVet approved

    It is used as a bronchodilator in asthma.

  5. Drug

    CX-052075

    go.drugbank.com/drugs/DB31655
    Approved

    [L53408] It is the primary ingredient in mNEXSPIKE, a COVID-19 mRNA vaccine developed by Moderna. … [L53413,A274083] mNEXSPIKE was approved by the US FDA in June 2025 for use in patients who have been previously vaccinated with any COVID-19 vaccine and who are at a higher risk of severe outcomes from

  6. Drug

    Paltusotine

    go.drugbank.com/drugs/DB16277
    ApprovedInvestigational

    [A274476] Paltusotine was approved by the FDA on September 25, 2025 for the treatment of acromegaly in adults.[L54061] … Paltusotine is a selective somatostatin receptor agonist: It mimics the biological actions of endogenous somatostatin, which activates the somatostatin 2 receptor (SST2) to block the secretion of growth

  7. Drug

    PEG-uricase

    go.drugbank.com/drugs/DB05321
    Investigational

    of severe, treatment-refractory gout in the United States in 2006. … PEG-uricase, a polyethylene glycol ("PEG") conjugate of recombinant porcine uricase (urate oxidase), which breaks down the uric acid deposits is being studied in Phase III clinical trials for the treatment

    Categories: Compounds used in a research, industrial, or household setting
  8. Drug

    Pimavanserin

    go.drugbank.com/drugs/DB05316
    ApprovedInvestigational

    In fact, pimavanserin is the first antipsychotic drug without D<sub>2</sub> blocking activity. … [A232783] It was approved by the FDA in April 2016 for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis thanks to favorable results from a pivotal six-week, randomized

  9. Drug

    Tisotumab vedotin

    go.drugbank.com/drugs/DB16732
    ApprovedInvestigational

    [A238914] On September 20, 2021, the FDA granted accelerated approval to tisotumab vedotin for the treatment of recurrent or metastatic cervical cancer in adults in whom the disease progressed during … The approval was based on tumour response and the durability of the response as demonstrated in InnovaTV 204 (NCT03438396): in this trial, the objective response rate was 24% and the median response duration

  10. Drug

    Clozapine

    go.drugbank.com/drugs/DB00363
    ApprovedInvestigational

    Despite its effectiveness in treating both positive and negative symptoms of schizophrenia, clozapine was briefly removed from the market in various jurisdictions in 1970 due to severe agranulocytosis. … This low affinity to dopamine receptors results in fewer extrapyramidal side effects, especially tardive dyskinesia.